Heated calls for WHO to drop controversial anticounterfeiting initiative
This article was originally published in Scrip
Debate is raging over what role the World Health Organisation should have with the secretive International Medical Products Anti-Counterfeiting Taskforce (IMPACT) that it is hosting, with NGOs wanting the WHO to disengage to safeguard its credibility, but the pharmaceutical industry believing that it has a key role to play.
You may also be interested in...
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.